| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0014-2999(01)01432-7 |
| P698 | PubMed publication ID | 11755147 |
| P2093 | author name string | Yamamoto H | |
| Hirose K | |||
| Kihara H | |||
| Yoshimoto R | |||
| Koganei H | |||
| P2860 | cites work | Serotonin release into plasma during common carotid artery thrombosis in rats | Q33216922 |
| Serotonergic Receptor Subtypes and Vascular Reactivity | Q40112563 | ||
| Retrospective analyses for hypothesis generation. A commentary on the PACK trial (prevention of atherosclerotic complications with ketanserin). | Q41297627 | ||
| Antithrombotic effects in a rat model of aspirin-insensitive arterial thrombosis of desethyl KBT-3022, the main active metabolite of a new antiplatelet agent, KBT-3022. | Q42548747 | ||
| Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries | Q42651476 | ||
| Local effect of serotonin released during coronary angioplasty | Q72088366 | ||
| Inhibition of 5-hydroxytryptamine-induced and-amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist | Q72768706 | ||
| AT-1015, a novel serotonin (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2A receptors and prevents the laurate-induced peripheral vascular lesion in rats | Q73697435 | ||
| The PACK trial: morbidity and mortality effects of ketanserin. Prevention of Atherosclerotic Complications | Q74453608 | ||
| 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function | Q77425309 | ||
| Serotonin is associated with coronary artery disease and cardiac events | Q78077693 | ||
| P433 | issue | 2-3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | thrombosis | Q261327 |
| P304 | page(s) | 157-162 | |
| P577 | publication date | 2001-12-01 | |
| P1433 | published in | European Journal of Pharmacology | Q1376712 |
| P1476 | title | Antithrombotic activity of AT-1015, a potent 5-HT(2A) receptor antagonist, in rat arterial thrombosis model and its effect on bleeding time | |
| P478 | volume | 433 |
| Q27348866 | A Novel Model of Intravital Platelet Imaging Using CD41-ZsGreen1 Transgenic Rats |
| Q44114280 | AT-1015, a newly synthesized 5-HT2 receptor antagonist, dissociates slowly from the 5-HT2 receptor sites in rabbit cerebral cortex membrane |
| Q34953029 | Deletion of the serotonin transporter in rats disturbs serotonin homeostasis without impairing liver regeneration |
| Q33435199 | Endobrevin/VAMP-8-dependent dense granule release mediates thrombus formation in vivo |
| Q38799483 | Exercise performance and peripheral vascular insufficiency improve with AMPK activation in high-fat diet-fed mice |
| Q80490295 | Hemostatic properties of a venomic protein in rodent dermal injuries |
| Q46892256 | Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery |
| Q42166606 | Insurmountable antagonism of AT-1015, a 5-HT2 antagonist, on serotonin-induced endothelium-dependent relaxation in porcine coronary artery |
| Q47393214 | Lung Endothelium Targeting for Pulmonary Embolism Thrombolysis |
| Q44961036 | Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy |
| Q35814472 | Sarpogrelate: cardiovascular and renal clinical potential |
| Q35117079 | The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation |
Search more.